Biomarkers of liver injury
View Patent ↗Novel, sensitive and specific markers for diagnostics and monitoring of liver injuries, including, but not limited to ischemic liver damage, are provided. This includes identification of several enzymes of arginine/urea/nitric oxide cycle, sulfuration enzymes and spectrin breakdown related products, among others.
1. A method for detecting physical liver damage in a subject, comprising:
detecting the presence of arginosuccinate synthetase (ASS), and at least one of sulfotransferase 2A1 (SULT2A1) and carbamoylphosphate synthase-1 (CPS-1) in a biological sample of a subject suspected of having been exposed to at least one hepatotoxic substance wherein an increased amount of ASS one hour after exposure and an increased amount of at least one of SULT2A1 or CPS-1 after up to about 24 hours of exposure compared to a normal subject not exposed to at least one hepatotoxic substance is indicative of physical liver damage.
2. The method of claim 1 wherein the hepatotoxic substance is a chlorinated hydrocarbon.
3. The method of claim 2 wherein the chlorinated hydrocarbon is carbon tetrachloride.
4. The method of claim 1 wherein the hepatotoxic substance is D-galactosamine.
5. The method of claim 1 wherein the hepatotoxic substance is a bacterial endotoxin and D-galactosamine.
6. The method of claim 5 wherein the bacterial endotoxin is LPS.
7. The method of claim 1 wherein the biological sample is liver tissue, blood, serum, plasma, liver cells, urine, tears or saliva.
8. The method of claim 1 wherein the at least one hepatotoxic substance is the combination of D-galactosamine and bacterial endotoxin LPS.
9. The method of claim 8 wherein ASS plasma levels about 72 hours after exposure of a subject suspected of having liver damage to bacterial LPS and D-glucosamine are comparable to ASS plasma levels in a normal subject.
10. The method of claim 1 wherein the hepatotoxic substance is Methylenedioxymethamphetamine (MDMA).
11. The method of claim 10 wherein the MDMA exposure is about 40 mg/kg.
12. The method of claim 11 wherein CPS-1 and SULT2A1 plasma levels are increased compared to levels in normal subjects not exposed to up to 40 mg/kg MDMA.
13. The method of claim 1 further comprising detecting for the presence of alanine transaminase (ALT) in the biological sample.
14. A process for detecting physical liver damage in a subject, comprising:
collecting a sample of a bodily fluid or a tissue in contact with liver tissue from a subject suspected of having been exposed to at least one hepatotoxic substance or a bacterial endotoxin; and
analyzing said sample or a fraction thereof for an amount of sulfotransferase 2A1(SULT2A1); and
optionally analyzing said sample or a fraction thereof for at least one additional protein biomarker associated with physical liver damage; and correlating the presence or amount of the detected protein biomarkers with the presence or type of physical liver damage in the subject;
wherein an increased amount of SULT2A1 levels compared to a normal subject not exposed to at least one hepatotoxic substance is indicative of physical liver damage.
15. The process of claim 14 wherein said optional additional protein biomarker is selected from the group consisting of arginosuccinate synthetase (ASS), alanine transaminase (ALT), carbamoylphosphate synthase-1 (CPS-1) or combinations thereof.
16. The process of claim 14 wherein the optional additional protein biomarker is ASS and an increased amount of ASS one hour after exposure and an increased amount of SULT2A1 or an additional protein biomarker selected from the group of CPS-1 and ALT after up to about 24 hr of exposure compared to a normal subject not exposed to at least one hepatotoxic substance is indicative of physical liver damage.
17. The process of claim 14 wherein the biological sample is liver tissue, blood, serum or plasma.
18. A kit using the method of claim 14 , the kit comprising:
(a) a substrate for holding a biological sample isolated from a human subject,
(b) an agent that specifically interacts with SULT2A1;
(c) an optional additional agent that specifically interacts with at least one additional protein biomarker upon contact with said sample; and
(d) printed instructions for reacting the agent and the optional additional agent with the sample or a portion of the sample to detect the presence or amount of the biomarker for diagnosing a damaged nerve cell in the subject;
wherein said optional additional protein biomarker is selected from the group consisting of arginosuccinate synthetase (ASS), alanine transaminase (ALT), carbamoylphosphate synthase-1 (CPS-1) or combinations thereof.
19. The kit of claim 18 , wherein the agent is an antibody that specifically and independently binds to its respective enzyme biomarker.